Seattle Genetics – From The Pharmacy To The Market
Will the success of Seattle Genetics make it a target for achievement or an attraction for success in the provincial business?
The Chief Executive Officer (CEO) and creator of Seattle Genetics is Clay Siegall. Seattle Genetics is studying human antibodies by maneuvering and wrapping it into medicine since 1998. The company has the ability to take the antibodies and turn it into therapy. A toxic charge is put into the cancer cells by antibodies to eradicate it from within. This method could launch Seattle Genetics into the major-league. They are hoping to become a major biotech drug company in Seattle.
Seattle Genetics employs 900 workers and has a market value of almost $10 billion. It is among the biggest biotech company in Washington. The goal of Seattle Genetics is to be one of the few companies that go from biotech to a big pharmaceutical company. They intend to add 200 employees to the company and they invest lavishly in marketing and research.
Seattle Genetics uses Adcetric to treat diseases such as Hodgkin lymphoma, that affects the lymphatic system and is cancerous. This disease can affect other organs in the body. These tests have positive results but are costly. The sales of the drugs have been lucrative. According to Clay Siegall, they are an upcoming worldwide company that manufactures many products and study cancer. The intent of the company is to build a tremendous organization instead of selling only to larger companies as other biotech corporations do.
It is obvious that Clay Siegal’s passion is to go above the biotech’s ordinary core on drug expansion toward conducting all the complications of worldwide marketing of its latest drugs. Clay Siegall opened a business in Switzerland to enable Seattle Genetics to conduct its personal marketing.
Clay Siegal, Ph.D. attended the University of Maryland. He has a Bachelor of Science degree in the field of Zoology. He attended the George Washington University where he studied Genetics and graduated with a Doctor of Philosophy degree.
Dr. Siegal received two honors and awards as Alumnus of the Year for computer, math and Natural Science and was named Entrepreneur of the Year. He was on the Board of Directors at Ultragenyx Pharmaceutical for four years. Dr. Siegel served on the Board of Director at Mirna Therapeutics, Inc. for 5 years. He served on the Board of Directors at Alder Biopharmaceuticals Inc. for twelve years.